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OBJECTIVES: Cirrhotic patients must receive an abdominal ultrasound every 6 months as part of hepatocellular
carcinoma (HCC) screening. The aim of this study was to assess if HCC screening was performed as recommended
by the literature and to observe the differences between the private and public services in Brazil.
METHODS: We analyzed data from the HCC screenings of 253 cirrhotic patients from the University Hospital
(n=177) and private sector (n=76) in Vito´ria, ES, Brazil.
RESULTS: Ultrasound screening was performed every 13.1 months on average (SD 9.02). In 37 out of 253
patients, the screenings were performed close to the recommended frequency; 16 were performed every
6 months, and 21 were mostly performed during the follow-up period every 6 months. In the remaining 216
cases, ultrasounds were not performed according to the guidelines; for 106 patients, less than 50% of all
ultrasounds were performed every 6 months and 110 patients showed an interval greater than one year.
Patients from the private sector received ultrasound screenings near the ideal in 28.9% of cases, while patients
from the University Hospital received ultrasounds in only 8.4% of cases (po0.0001). HCC was diagnosed in 30
patients (11.8%). For these 30 patients, 11 screenings were properly performed within 6 months (36.6%) and
only 1 out of the 11 (9%) met the criteria for transplant. In the remaining 19 patients who did not receive the
screening within 6 months, 6 (31.5%) did not meet the criteria for transplant.
CONCLUSION: HCC screening in our environment was irregularly performed, mainly in the public service setting,
which prevented early diagnosis in a large number of patients.
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’ INTRODUCTION
Hepatocellular carcinoma (HCC) is the most common
primary tumor of the liver and represents more than 90% of
all primary liver cancer cases (1,2). The World Health
Organization considers HCC to be the third most common
cause of death by cancer in humans (3). Nearly 90% of HCC
cases are associated with liver cirrhosis, especially those
associated with the hepatitis B and C viruses (HBVand HCV,
respectively) and alcoholism; however, any type of cirrhosis
is a risk factor for tumor development (1,2).
Despite considerable progress in the treatment of HCC, the
prognosis remains poor because most patients present with
advanced liver disease when they are diagnosed, preventing the
use of therapeutic curative measures (4). Thus, HCC screenings
in high-risk populations aim to reduce mortality because they
may enable the identification of tumors at earlier stages and the
use of therapeutic curative measures. Combining alpha-fetopro-
tein (AFP) measurement and abdominal ultrasound (US)
improves HCC detection rates. It was initially suggested that
US screenings should be conducted at 6-month intervals based
on tumor doubling times. Shorter time intervals, such as every 3
months, may increase the detection of smaller nodules but have
shown no significant effects on survival (5).
HCC screening is recommended for patients with cirrhosis of
any etiology, Child-Pugh A and B (or Child-Pugh C if awaiting
a liver transplant), non-cirrhotic disease with either a chronic
HBV diagnosis or a family history of HCC and chronic carriers
of HCV with advanced hepatic fibrosis (Metavir 3) (2). The
objective of this study was to assess if HCC screening was
performed as recommended by the literature and to observe
whether the differences between public and private services
interfere with early HCC diagnosis.DOI: 10.6061/clinics/2016(07)01
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’ MATERIALS AND METHODS
This was a descriptive, cross-sectional study from October
2012 to May 2014 that used a retrospective analysis of the
medical records of 253 cirrhotic patients. In total, we
recruited 177 (70.0%) patients who required services from a
reference unit at the Study of Liver Diseases University
Hospital Cassiano A Moraes (UH) and 76 patients (30.0%)
who required services from the private sector (PS). The
follow-up was performed using the same criteria for both
services. We included cirrhotic patients with any etiology
who had been followed for at least 6 months within the last
10 years.
Demographic data, etiologies of cirrhosis, time intervals
between cirrhosis diagnosis and HCC detection, time
intervals between the US screenings during follow-up and
the ultrasonography findings at every examination were
retrieved from each record.
Liver cirrhosis was diagnosed according to clinical data
in addition to an imaging method (i.e., computed tomo-
graphy [CT] or nuclear magnetic resonance imaging
[NMR], US), endoscopy or pathology. Alcohol abuse was
defined as more than 60 g of ethanol intake per day for men
and more than 30 g per day for women for at least 10 years.
Persistent HBV infection was assessed by evaluating HBsAg
and HCV infection using anti-HCV antibodies associated
with PCR (polymerase chain reaction) to identify the RNA
virus. Cirrhosis secondary to nonalcoholic steatohepatitis
was diagnosed by the presence of metabolic syndrome after
excluding other possible causes of chronic liver disease.
Metabolic syndrome was diagnosed according to the
criteria of the Brazilian Society of Endocrinology and
Metabolism (6).
To characterize the time interval between abdominal US
screenings during the follow-up program in private and
public services, patients were separated into the following
groups: 1) US every 6 months, defined as all US examina-
tions performed within a time interval of 6 months; 2) most
US within 6 months, defined as when more than 50% of all
US screenings performed during follow-up were conducted
every 6 months; 3) minority of US within 6 months, defined
as when less than 50% of all US screenings performed during
follow-up were conducted every 6 months; or 4) US after
more than 1 year, defined as when more than 50% of all US
screenings were performed with an interval of 1 year or
more.
All patients had access to AFP measurement tests. The cut-
off value of serum AFP was 10 ng/ml. Values over 10 ng/ml
were considered to be abnormal and were suspicious for the
presence of HCC. The size of the nodule evaluated at the time
of HCC diagnosis was categorized as follows: 1) two or three
nodules up to 3 cm, 2) one nodule up to 5 cm and 3) one
nodule greater than 5 cm. Laboratory tests (HBsAg, anti-HCV
antibodies, PCR for HCV RNA and serum AFP) were
performed at the University Hospital for public sector patients
and privately owned laboratories for private sector patients.
Patients were considered to have received regular medical
follow-ups if they went to doctors’ appointments at least
every 12 months.
The software Statistical Package for the Social Sciences (SPSS,
version 17.0 IBM, Chicago, IL, USA) was used for statistical
analysis. Frequencies were compared by chi square test or exact
Fisher test. Student’s t test was utilized to compare age. A p
value less than 0.05 was considered significant.
Ethical considerations
This study was approved by the ethics committee of the
Federal University of Espírito Santo under registration
number 254.604.
’ RESULTS
The US screening was performed every 13.1 months on
average (SD 9.02). Among UH patients, the mean interval
between US was of 14.9 months and 11.4 months among
PS patients (po0.001).
Demographic data, etiologies of liver cirrhosis, and reg-
ularity of US by the origin of the patients are shown in Table 1.
The main isolated cause of cirrhosis was chronic alcoholism
(42.4% versus 24.9% HBV and 18.1% HCV; p=0.018) in the UH
group and HCV infection (38.2% versus 27.6% alcoholism and
10.5% HBV; po0.05) in the PS group. The time intervals
between US examinations were higher in the UH group than
in the PS group (po0.05). In addition, the time interval
between US was significantly higher among patients who did
not receive regular follow-ups (Table 2).
The mean time of follow-up was 65.43 months (SD 47.44;
median 49). Thirty patients had an HCC diagnosis (11.8%), and
the mean time between liver cirrhosis diagnosis and HCC
diagnosis was 43.7±36.4 months (median 26 months).
During follow-up, 35 patients had a nodule identified by
US and four patients had nodules identified by CT or MR to
confirm suspicions after US or AFP. HCC was diagnosed in
26 of the 35 patients through nodule identification by US and
HCC was diagnosed in all four patients through nodule
identification by another imaging method. Among the
30 cases of HCC, 16 were from the UH and 14 from PS.
The size and number of nodules detected during the follow-
up period are shown in Tables 3 and 4 according to service
type and frequency of US screening, respectively. An HCC
diagnosis was established with greater frequency when the
abdominal US was performed as recommended in the
literature (p=0.006), and the greatest number of cases was
identified among patients with HCV cirrhosis (12 cases HCV,
9 ethanol, 6 HBV, 2 NASH and 1 cryptogenic; p=0.021).
AFP was higher than 10 ng/ml in 47 patients; of these,
17 had HCC. However, in 13 cases of HCC (43.3%), the AFP
level was normal. In three patients whose US did not show
any nodules, the AFP levels were notably elevated, and other
imaging methods were used to demonstrate HCC.
Table 4 shows the distribution of nodule size in relation to
the frequency of abdominal US screening. Patients who had
US screenings performed at time intervals longer than 1 year
had the most cases with nodules larger than 5 cm identified
at the time of diagnosis.
’ DISCUSSION
Despite considerable progress in the treatment of HCC, the
prognosis remains poor because most patients present with
advanced liver disease when they are diagnosed, preventing
the use of therapeutic curative measures (4). Our results
confirm that screening performed irregularly does not allow
early diagnosis of HCC in a high percentage of patients (7,8).
The procedure of performing an abdominal US every
6 months for cirrhotic patients is cost effective (9), and this
recommendation is internationally accepted, including by
the public health system of Brazil (2,10).
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The public health system in Brazil does not specifically
recommend whether a US should be performed with or without
AFP evaluation. Our results showed that although the AFP
results were normal in 43% of diagnosed HCC cases, high serum
AFP was observed in three HCC cases with normal US. For this
reason, we believe that AFP measurement is a tool that must be
performed with US to screen for HCC in cirrhotic patients;
however, many authors have suggested otherwise (11).
Despite the effectiveness of the procedure, there was great
scheduling irregularity of HCC screening in the studied sample,
especially in the public service setting. As Table 1 shows, half of
the patients from the public service setting received US at
intervals greater than 12 months. The adherence to screening
observed here (50%) was inferior to that reported in a Californian
study by Wong et al. (12) who described 64.2% to be ideal, and
our adherence was also much lower than the 74.7% observed in
884 patients with liver cirrhosis at a public service hospital in the
city of São Paulo (13). Patient adherence to screening partly
depends on the attending physician, who must request tests and
convince the patient of the importance and benefits of screening.
At UH, the team of professionals who worked in the liver unit is
composed of experienced gastroenterologists and hepatologists
who are attentive to the needs and importance of HCC screening
in cirrhotic patients. However, patients’ adherence may be
influenced by other factors, including difficulties in scheduling
appointments and tests that are generally performed long after
they were requested in the public system of health in Espírito
Santo. This delay may negatively influence patients’ adherence
to the screening programs.
When we compared the patients from the UH and PS
groups, adherence was significantly greater in the private
group partly due to an enhanced ability to perform the
screening without delay. Another factor that might have
negatively influenced patients’ adherence in the UH
group was that patients with cirrhosis of an alcoholic
etiology formed the majority of this group. Indeed,
alcoholics are known to be poorly adherent to medical
care (14).
In this study, regular follow-up was shown to be a relevant
factor associated with regular US examinations. This observation
agreed with data that were previously reported by Wong et al.
(12), who demonstrated that the number of annual doctors’
appointments was the only positive predictor for US examina-
tion in a screening program of cirrhotic patients.
In conclusion, our results showed that adherence to HCC
screening in cirrhotic patients in our environment was low,
mostly among patients attending public service centers. Poor
adherence was likely due to the lengthy time between test
requests and fulfillments.
Table 2 - Evaluation between regular medical appointment and
ultrasound performance for hepatocellular carcinoma screening.
Variables Regular medical appointment p-value
Yes (n=181) No (n=72)
Time between US n (%)
US every 6 months 13 (7.2) 3 (4.2) 0.199
US most in 6 months 19 (10.4) 2 (2.8) 0.019
US minority in 6 months 91 (50.5) 14 (19.4) o0.001
US over 1 year 58 (31.9) 53 (73.6) o0.001
Table 1 - Demographic data, etiologies of liver cirrhosis and regularity of ultrasound performance according to type of public and
private patients.
Variables Groups* All cases (n=253) p-value**
UH (n=177) PS (n=76)
Gender n (%)
Male 131 (74) 52 (68.4) 183 0.417
Age (mean±SD) 52.00±12.05 56.00±12.03 52.65±12.2 0.553
Cirrhosis etiology n (%)
Alcoholism 75 (42.4) 21 (27.6) 96 (37.9) 0.018
HBV 28 (15.8) 7 (9.2) 35 (13.8) 0.113
HBV+ alcoholism 16 (9.1) 1 (1.3) 17 (6.7) 0.016
HCV 23 (12.9) 22 (28.9) 45 (17.7) 0.002
HCV + alcoholism 9 (5.2) 7 (9.3) 16 (6.3) 0.169
NASH 14 (7.9) 8 (10.5) 22 (8.6) 0.324
Others 12 (6.7) 10 (13.2) 22 (8.6) 0.148
Regular follow-up n (%)
Yes 129 (72.8) 52 (68.4) 181 (71.5) 0.497
No 48 (27.2) 24 (31.6) 72 (28.5)
Time between US***n (%)
US every 6 months 8 (4.5) 8 (10.5) 16 (6.3) 0.045
US most in 6 months 7 (3,9) 14 (18.4) 21 (8.3) 0.002
US minority in 6 months 71 (40.2) 35 (46.1) 106 (41.8) 0.192
US over 1 year 91 (51.4) 19 (25.0) 110 (43.4) 0.001
*UH=University Hospital; PS=private sector
**Comparison between UH versus PS
***US=Ultrasound
Table 3 - Size and number of nodules of hepatocellular carcinoma
diagnosed in patients with liver cirrhosis who were followed-up at
the University Hospital or private sector in Vito´ria, ES, Brazil.
Nodule size Group p-value
UH n=16 PS n=14
2 or 3 nodule up to 3 cm n (%) 5 (31.2%) 7 (50%) 0.358
1 nodule 3 up to 5 cm n (%) 7 (43.8%) 4 (28.6%) 0.584
Larger than 5 cm n (%) 4 (25.0%) 3 (21.4%) 0.706
*Hepatocellular carcinoma
**UH=University Hospital; PS=private sector
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